Share on StockTwits
 

Vanda Pharmaceuticals (NASDAQ:VNDA) announced its earnings results on Thursday. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.20) by $0.03, AnalystRatingsNetwork.com reports. The company had revenue of $8.80 million for the quarter, compared to the consensus estimate of $8.50 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 12.56 on Thursday. Vanda Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $15.65. The stock has a 50-day moving average of $12.42 and a 200-day moving average of $11.04. The company’s market cap is $416.9 million.

VNDA has been the subject of a number of recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Vanda Pharmaceuticals in a research note on Tuesday, November 26th. They set an “overweight” rating and a $21.00 price target on the stock. On the ratings front, analysts at Jefferies Group raised their price target on shares of Vanda Pharmaceuticals from $13.00 to $20.00 in a research note on Friday, November 15th. They now have a “buy” rating on the stock. Finally, analysts at JMP Securities set a $23.00 price target on shares of Vanda Pharmaceuticals in a research note on Friday, November 15th. They now have a “market outperform” rating on the stock. Six investment analysts have rated the stock with a buy rating, Vanda Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $18.68.

Vanda Pharmaceuticals Inc (NASDAQ:VNDA) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.